| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,518,000 |
| Market
Cap: |
10.23(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.2 - $16.52 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
13,504 |
24,904 |
24,904 |
44,341 |
| Total Sell Value |
$82,239 |
$159,016 |
$159,016 |
$166,208 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
5 |
11 |
11 |
16 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2021-06-28 |
4 |
AS |
$5.77 |
$43,771 |
D/D |
(7,586) |
296,274 |
|
-62% |
|
| Chen Hongming |
CHIEF SCIENTIFIC OFFICER |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$14,148 |
D/D |
(2,452) |
240,563 |
|
-62% |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2021-06-28 |
4 |
AS |
$5.77 |
$14,148 |
D/D |
(2,452) |
126,115 |
|
-62% |
|
| Paull Robert Bradley |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
|
- |
|
| Shah Rajeev M. |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Koven Andrew I |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
53,000 |
|
- |
|
| Grunberg Gregory |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
|
- |
|
| Perry Gregory D |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
|
- |
|
| Rosen Howard B |
|
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
44,824 |
|
- |
|
| Chen Hongming |
Chief Scientific Officer |
• – – |
2021-03-01 |
4 |
OE |
$2.30 |
$21,850 |
D/D |
9,500 |
243,015 |
|
- |
|
| Chen Hongming |
Chief Scientific Officer |
• – – |
2021-02-25 |
4 |
OE |
$2.30 |
$108,100 |
D/D |
47,000 |
233,515 |
|
- |
|
| Chen Hongming |
Chief Scientific Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
22,666 |
186,515 |
|
- |
|
| Brazzell Kim |
Chief Medical Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
303,996 |
|
- |
|
| Trachtenberg Eric |
See Remarks |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
22,666 |
128,567 |
|
- |
|
| Bazemore Todd |
Chief Operating Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
137,500 |
|
- |
|
| Iwicki Mark T |
Chief Executive Officer |
• • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
76,000 |
303,860 |
|
- |
|
| Reumuth Mary |
Chief Financial Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
22,666 |
147,959 |
|
- |
|
| Chen Hongming |
Chief Scientific Officer |
• – – |
2020-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
61,000 |
163,849 |
|
- |
|
| Bazemore Todd |
Chief Operating Officer |
• – – |
2020-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
81,000 |
110,000 |
|
- |
|
| Trachtenberg Eric |
See Remarks |
• – – |
2020-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
61,000 |
105,901 |
|
- |
|
| Iwicki Mark T |
Chief Executive Officer |
• • – |
2020-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
178,300 |
227,860 |
|
- |
|
| Reumuth Mary |
Chief Financial Officer |
• – – |
2020-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
61,000 |
125,293 |
|
- |
|
| Brazzell Kim |
Chief Medical Officer |
• – – |
2020-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
81,000 |
276,496 |
|
- |
|
| Bazemore Todd |
Chief Operating Officer |
• – – |
2020-10-22 |
4 |
B |
$7.60 |
$304 |
I/I |
40 |
42 |
1.91 |
-9% |
|
| Bazemore Todd |
Chief Operating Officer |
• – – |
2020-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
19,000 |
29,000 |
|
- |
|
149 Records found
|
|
Page 4 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.03 (0.5%) 
